Skip to main content

CNS Pharmaceuticals, Inc.

CNSP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001729427

In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by CNS Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $10.0K in total
Open-market sells
0 filings
Insiders trading
1
Net value
+$10.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for CNS Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for CNS Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Fisher MichalDirector2,000Aug 18, 20261
Levin RamiCEO and President4,750Aug 18, 20262
Charles Faith L.Director7,100May 20, 20262
O'Loughlin SteveChief Financial Officer–Mar 4, 20261
Faulkner EricChief Technology Officer–Mar 4, 20261
Climaco John MChief Executive Officer215,676Nov 19, 20251
Keyes Jeffry R.Director11,100Nov 19, 20251
Downs ChristopherChief Financial Officer103,438Nov 19, 20251
Gumulka JerzyDirector43,006Nov 19, 20251
Cockroft Bettina M.Director–Nov 19, 20251
Mahery AmyDirector–Nov 19, 20251
Cortice Biosciences, Inc.10% Owner–Aug 6, 20240
Evans Carl AnthonyDirector33,458Apr 10, 20240
Andraczke AndrzejDirector–Oct 12, 20230
Priebe Waldemar10% Owner156,807IndirectAug 1, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 18, 2026 (view filing)9:01 AM ETMay 1892 daysLateFisher MichalDirectorPPurchase+2.00K$5.00+$10.0KNew position2.00K after
May 20, 2026 (view filing)May 182 daysCharles Faith L.DirectorPPurchase+7.10K$4.79+$34.0KNew position7.10K after
Feb 6, 2024 (view filing)10:28 AM ETFeb 15 daysLateGumulka JerzyDirectorPPurchase+33.3K$0.30+$10.0K+344.6%43.0K after
Feb 6, 2024 (view filing)10:27 AM ETFeb 15 daysLateEvans Carl AnthonyDirectorPPurchase+33.3K$0.30+$10.0K+26,666.4%33.5K after
Feb 6, 2024 (view filing)10:27 AM ETFeb 15 daysLateDowns ChristopherChief Financial OfficerPPurchase+66.7K$0.30+$20.0K+181.3%103.4K after
Feb 6, 2024 (view filing)10:27 AM ETFeb 15 daysLateClimaco John MChief Executive OfficerPPurchase+166.7K$0.30+$50.0K+340.1%215.7K after
Aug 23, 2023 (view filing)Aug 221 dayDowns ChristopherChief Financial OfficerPPurchase+27.0K$1.27+$34.3K+276.3%36.8K after
Aug 16, 2023 (view filing)Aug 16Same dayClimaco John MChief Executive OfficerPPurchase+2.75K$1.80+$4.95K+5.9%49.0K after
Aug 1, 2023 (view filing)Dec 6, 2022-Mar 28, 2023238 daysLatePriebe Waldemar10% OwnerSSale−94.3K$1.41−$133.1K−37.6%156.8K after17 lots10b5-1
Apr 21, 2023 (view filing)Apr 192 daysGumulka JerzyDirectorPPurchase+2.50K$1.70+$4.25K+34.9%9.67K after
Apr 18, 2023 (view filing)Apr 171 dayDowns ChristopherChief Financial OfficerPPurchase+3.10K$3.20+$9.92K+50.4%9.25K after
Apr 17, 2023 (view filing)Apr 107 daysLateGumulka JerzyDirectorPPurchase+7.17K$0.74+$5.31KNew position7.17K after
Apr 14, 2023 (view filing)Apr 122 daysClimaco John MChief Executive OfficerPPurchase+15.0K$0.69+$10.3K+50.0%45.0K after
Dec 7, 2021 (view filing)Dec 61 dayDowns ChristopherChief Financial OfficerPPurchase+5.00K$0.94+$4.70K+3.4%151.5K after
Nov 22, 2021 (view filing)Nov 193 daysDowns ChristopherChief Financial OfficerPPurchase+4.50K$1.15+$5.17K+3.2%146.5K after